index,Regulator Name,Regulator Type,Regulator Subtype,Regulator HGNC Symbol,Regulator Database,Regulator ID,Regulator Compartment,Regulator Compartment ID,Regulated Name,Regulated Type,Regulated Subtype,Regulated HGNC Symbol,Regulated Database,Regulated ID,Regulated Compartment,Regulated Compartment ID,Sign,Connection Type,Mechanism,Site,Cell Line,Cell Type,Tissue Type,Organism,Unnamed: 0,Score,Source,Statements,Paper IDs,Evidence Score,Match Score,Kind Score,Epistemic Value,Total Score
315,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,atm,protein,,atm,uniprot,q13315,nucleus,go:0005634,positive,i,activated by,nucleus,,germ,female genital,mouse,['54'],nan,nan,"other chk2 activities independent of exogenous damaging sources have been described to occur during meiosis in experimental models. in c. elegans, chk2 is essential for meiosis since it participates in chiasma formation and in crossover events (higashitani et al., 2000). in d. melanogaster a role for chk2 at the meiotic checkpoint is controversial (abdu et al., 2002; masrouha et al., 2003). in the same organism, the absence of chk2 leads to the accumulation of abnormal nuclei in the syncytial embryo, resulting probably from defects in arresting or eliminating cells with endogenous dna damage (pushpavalli et al., 2013). in mice, chk2 is activated by atm in female germ cells during early meiosis (miles et al., 2010) and regulates cell cycle progression and spindle assembly during oocyte maturation and early embryo development (dai et al., 2014). moreover, chk2 induces the removal of oocytes with unrepaired meiotic or induced dsbs by activating p53 and p63. thus, chk2 ablation can reverse female mice infertility caused by meiotic recombination defects or irradiation (bolcun-filas et al., 2014).",pmc4296918,1,10,20,1,30
316,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,atm,protein,,atm,uniprot,q13315,nucleus,go:0005634,positive,i,phosphorylation,,,,,,['39'],nan,nan,"several proteins phosphorylated by chk2 are also substrates of atm, including brca1, brca2, kap-1, and p53 (banin et al., 1998; gatei et al., 2000; wang et al., 2004; white et al., 2006; matsuoka et al., 2007) suggesting that chk2 reinforces or redirects atm function. despite the identification of >20 chk2 substrates so far, a large-scale proteomics analysis of cellular proteins phosphorylated by this kinase, as has been done for atm and atr (matsuoka et al., 2007), has not yet been reported. such a study would help clarify roles of chk2 in the ddr and in normal cell physiology.",pmc4296918,1,10,20,1,30
662,mek1,protein,,,uniprot,p36507,cytoplasm,go:0005737,raf,protein,,,uniprot,p04049,cytoplasm,go:0005737,negative,i,feed-back inhibition,erk,,,,,['1982'],nan,nan,"some scientists and clinicians have considered that the simultaneous targeting of raf and mek by individual or dual inhibitors may be more effective in cancer therapy than just targeting raf or mek by themselves. this is based in part on the fact that there are intricate feed-back loops from erk which can inhibit raf and mek. for example when mek1 is targeted, erk1,2 is inhibited and the negative feed-back loop on mek is broken and activated mek accumulates. however, if raf is also inhibited, it may be possible to completely shut down the pathway. this is a rationale for treatment with both mek and raf inhibitors or dual inhibitors. likewise targeting both pi3k and mtor may be more effective than targeting either pi3k or mtor by themselves. if it is a single inhibitor which targets both molecules, such as the new pi3k and mtor dual inhibitors this becomes a realistic therapeutic option. finally, an emerging concept is the targeting of two different signal transduction pathways, raf/mek/erk and pi3k/pten/akt/mtor for example. this has been explored in some preclinical models as well as clinical trials. the rationale for the targeting of both pathways may be dependent on the presence of mutations in either/or both pathways or in upstream ras in the particular cancer which can activate both pathways. the concepts of targeting these pathways is considered in more detail in an accompanying review [134].",pmc3660063,1,10,20,1,30
879,pik3ca,protein,oncogene,,uniprot,p42336,,,p53,protein,tumor suppressor,tp53,uniprot,p04637,,,negative,i,transcriptional inhibition,,,epithelial,tumors,human,['3639'],nan,nan,"in another study, pik3ca was identified as an oncogene involved in squamous cell carcinomas [384]. simultaneous abnormalities in both pathways were rare in primary tumors, suggesting that amplification of pik3ca and mutation of p53 are mutually exclusive events and either event is able to promote a malignant phenotype [384]. moreover, the negative effect of p53 induction on cell survival involved the transcriptional inhibition of pik3ca that was independent of pten activity, as pten was not expressed in the primary tumors [384]. conversely, constitutive activation of pik3ca resulted in resistance to p53-related apoptosis in pten deficient cells [384]. thus, p53 regulates cell survival by inhibiting the pi3k/akt prosurvival signal independent of pten in epithelial tumors. this inhibition is required for p53-mediated apoptosis in malignant cells [384].",pmc2652403,1,10,19,1,29
875,pi3k,protein,,pik3ca,uniprot,p42336,,,hif-1,protein,transcription factor,,uniprot,q16665,nucleus,go:0005634,positive,i,activation,,,cancer,,human,['3607'],nan,nan,"pi3k signaling plays a key role in tumor angiogenesis, the development of new blood vessels. hypoxia develops in the majority of solid tumors due to the inability of the existing vascular system to supply the growing tumor mass with adequate amounts of oxygen [251]. a large body of clinical evidence suggests that intratumoral hypoxia correlates with the elevated aggressive behavior of cancer cells and their resistance to therapy, leading to poor patient prognoses [251]. hypoxia-inducible factor 1 (hif-1) is a transcriptional activator that functions as a master regulator of o2 homeostasis [252]. hif-1 target genes encode proteins that increase o2 delivery and mediate adaptive responses to o2 deprivation [252]. several hif-1 targets are known, including the gene encoding vascular endothelial growth factor (vegf). hif-1 activity is regulated by the cellular o2 concentration and by the major growth factor-stimulated signal transduction pathways [252]. in human cancer cells, both intratumoral hypoxia and genetic alterations affecting signal transduction pathways lead to increased hif-1 activity, which promotes angiogenesis, metabolic adaptation, and other critical aspects of tumor progression [252, 253]. hif-1 is a transcriptional activator composed of hif-1α and hif-1β subunits [253, 254]. under hypoxic conditions, hif-1α expression increases as a result of decreased ubiquitination and degradation [254]. the tumor suppressors vhl (von hippel-lindau protein) and p53 target hif-1α for ubiquitination such that their inactivation in tumor cells increases the half-life of hif-1α [254]. increased pi3k and akt or decreased pten activity in cancer cells were also shown to increase hif-1α [255]. a further study observed that hypoxic induction of hif-1α protein was decreased by serum deprivation in carcinoma cells under low oxygen tension [256]. over-expression of dominant-active akt1 restored hif-1α expression, whereas inhibition of pi3k activity reduced hypoxic hif-1α protein levels [256]. an immunohistochemical analysis of human breast cancers revealed that lack of akt1 phosphorylation correlates with low hif-1α levels [256]. the angiogenic switch in ras-transformed cells is promoted by the tumor microenvironment through the induction of the angiogenic mitogen, vegf. it was shown that hypoxia modulates vegf induction in ras-transformed cells through the activation of a stress inducible pi3k/akt pathway and the hif-1 transcriptional response element [257]. hypoxia was reported to activate a growth factor receptor (pdgfr)/pi3k/akt cascade that leads to gsk-3 inactivation, and thus impact on cell survival, proliferation, and metabolism [258]. it was also reported that under hypoxic conditions, rat pheochromocytoma pc12 cells are resistant to apoptosis induced by serum withdrawal and chemotherapy treatment. the hypoxia-dependent protection from apoptosis correlated with activation of the pi3k/akt pathway [259]. in another study, insulin and epidermal growth factor or an inactivating mutation in the tumor suppressor pten specifically increased the protein levels of hif-1α, but not of hif-1β in human cancer cell lines [260]. this specific elevation of hif-1α protein expression required pi3k signaling [260]. another study examined the involvement of foxo4 (also known as afx), a member of the forkhead transcription factor superfamily that is negatively regulated by the pi3k/akt pathway, in the regulation of hif-1α protein expression [261]. nuclear expression of foxo4 resulted in the suppression of various responses to hypoxia, including decreased vegf [261]. interestingly, foxo4 down-regulated the hif-1α protein levels, consistent with the lack of hypoxia responsiveness [261]. in another study, the linkage between mtor and hif-1 in pc-3 prostate cancer cells treated during hypoxia was further explored [262]. pretreatment of pc-3 cells with the mtor inhibitor, rapamycin, inhibited both the accumulation of hif-1α and hif-1-dependent transcription induced by hypoxia [262]. further work pinpointed the oxygen-dependent degradation domain as a critical target for the rapamycin-sensitive, mtor-dependent signaling pathway leading to hif-1α stabilization by hypoxia-inducing agents [262]. these studies position mtor as an upstream activator of hif-1 function in cancer cells and suggest that the anti-tumor activity of rapamycin is mediated, in part, through the inhibition of cellular responses to hypoxic stress [262].",pmc2652403,1,10,19,1,29
868,pi3k,protein,kinase,pik3ca,uniprot,p42336,cytoplasm,go:0005737,cyclin d1,protein,cyclin,ccnd1,uniprot,p24385,nucleus,go:0005634,negative,i,blocks,,,tumor,breast,human,['2972'],nan,nan,"mek and pi3k inhibition blocks møcm induced growth, but dissociates kinase activity from cyclin d1 expression. a-b: (a) lm2 or (b) jf32 cells were cultured alone (control), with 2 ng/ml migf-1 (+ igf-1) or with media conditioned by mh-s macrophages (+ møcm), and treated with 0.05% dmso (vehicle, ""veh""), 5 μm u0126 (u0), 10 μm ly294002 (ly) or both agents together (u + l). relative cell number was determined by mts, and mean + sd plotted as fold-change from vehicle control, which was normalized to 1.0. data was pooled from at least 3 independent experiments. * p < 0.05, ** p < 0.01 and *** p < 0.001 versus control for each treatment by 2-way anova. c-d: lm2 (c) or jf32 (d) cells were cultured as described above, and cell homogenates probed for protein expression as described. western blot images are representative of two independent experiments. e-i: densitometry data from all western blot replicates was collected from both lm2 and jf32 cell lines, combined, and presented as fold change (mean ± sem) from untreated vehicle control lanes at each time point (""veh -"" group normalized to 1, not shown). the legend colors indicate drug treatment groups, followed by a ""- or +"" to indicate the absence or presence of møcm, as in (a-b). * p < 0.05, ** p < 0.01 and *** p < 0.001 versus control (veh -) cells at each time point by 2-way anova.",pmc3135566,1,10,19,1,29
866,pi3k,protein,kinase,pik3ca,uniprot,p42336,cell membrane,go:0005886,mtor,protein,kinase,mtor,uniprot,p42345,cytoplasm,go:0005737,positive,i,phosphorylation,ser-2448,,cancer,,human,['939'],nan,nan,"the pi3k, akt, erk, and mtor prosurvival mediators are important therapeutic targets, as they are constitutively activated in many cancers and contribute to cancer progression by promoting cellular proliferation and inhibiting cell death signalling pathways (falasca, 2010). phosphoinositide 3-kinase (pi3k) is activated at the cell membrane by tyrosine kinase growth factor receptors, such as members of the epidermal growth factor receptor family (egfr and her-2), and by the insulin-like growth factor-1 receptor (igfr), as well as its downstream signalling substrate irs-1 (insulin receptor substrate-1; schlessinger, 2000). phosphoinositide 3-kinase promotes cancer cell survival by activation of downstream mediators akt and ras, the latter leading to erk activation (mccubrey et al, 2007). akt exerts its survival role via a diverse array of substrates, which control key cellular processes, including apoptosis, cell cycle progression, transcription, and translation (chang et al, 2003). a major downstream substrate of akt is the serine/threonine kinase mtor. akt can directly phosphorylate mtor at ser-2448 and activate it, as well as cause indirect activation of mtor by phosphorylating and inactivating tsc2 (tuberous sclerosis complex 2, also called tuberin). the raptor–mtor complex signals to its downstream effectors s6 kinase/ribosomal protein s6 (p70s6k) and the eif4e-binding protein (p4e-bp1) to control transcription and translation, which selectively regulates multiple proteins that control cell cycle and apoptosis (gibbons et al, 2009). additionally, akt can directly regulate apoptosis by phosphorylating and inactivating proapoptotic proteins such as bad and caspase-9 (datta et al, 1997; cardone et al, 1998; mabuchi et al, 2002). extracellular signal-regulated kinase (erk) exerts its antiapoptotic effects by phosphorylating and inactivating bad (mabuchi et al, 2002). as with most intracellular signalling cascades, cross-talk and negative and positive feedback loops complicate final signalling outcomes.",pmc3039802,1,10,19,1,29
825,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,ras,protein,,ras,uniprot,p01112,plasma membrane,go:0005886,negative,i,dependent,,fibroblasts,,mouse and human,mouse,['3362'],nan,nan,"p53- and retinoblastoma-dependent oncogene-induced senescence has been best characterised in response to activated ras signalling in mouse and human fibroblasts (serrano et al., 1997; ferbeyre et al., 2002), where increased p53 expression is dependent on an initial hyperproliferative phase induced by activated ras followed by accumulation of dna damage (di micco et al., 2006; mallette et al., 2007). importantly, here we show that pi3k/akt-induced senescence proceeds via a different mechanism to ras. it occurs rapidly, and is independent of dna damage. the rapid cell cycle arrest induced by akt hyperactivation implies that these cells are far less likely to escape senescence than cells with hyperactivating mutations in ras; thus, suggesting that somatic mutations in akt are unlikely to be the initial mutation in the multistep progression to tumourigenesis.",pmc3325598,1,10,19,1,29
824,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,pi 3-kinase,protein,,pik3ca,uniprot,p42336,plasma membrane,go:0005886,positive,i,downstream,,,,,human,['517'],nan,nan,"finally, we note that the function of p53 downstream of pi 3-kinase signaling may be relevant to tumor therapy with drugs targeting pi 3-kinase. mutations that activate pi 3-kinase signaling are frequently found in human cancers, and several inhibitors of pi 3-kinase are currently being evaluated in clinical trials.1, 2 mutations of p53 are also extremely common in human cancer,24, 26 and the role of p53 in inducing apoptosis downstream of pi 3-kinase signaling suggests that p53 mutations in tumors may confer partial resistance to pi 3-kinase inhibitors.",pmc3481126,1,10,19,1,29
45,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,igf-1r,protein,receptor,igf1r,uniprot,p08069,plasma membrane,go:0005886,positive,d,regulation,igf-1r,,pancreatic cancer cells,pancreas,human,['1971'],nan,nan,"pancreatic cancer cells have elevated igf-1r expression and it is well known that akt regulates igf-1r expression [369]. this akt effect on igf-1r has been suggested to be responsible for the invasiveness of pancreatic cancer cells. active src can also activate akt, and both src and akt up-regulate igf-1r expression in this cancer. it has been demonstrated that igf-i is expressed in the surrounding stromal cells but not in the cancer cells. this igf-1 expression may serve as a paracrine growth factor to activate the igf-1r pathway and the downstream ras/pi3k/akt/mtor pathway in pancreatic cells.",pmc3660063,1,10,19,1,29
909,pten,protein,,pten,uniprot,p60484,,,akt/pkb,protein,,akt1,uniprot,p31749,,,positive,i,phosphorylation,,,t lymphocytes,,mouse,['3630'],nan,nan,"a null mutation was introduced into the mouse pten gene by homologous recombination in embryonic stem (es) cells [352]. pten (-/-) es cells exhibited an increased growth rate and proliferated even in the absence of serum. es cells lacking pten function also displayed advanced entry into s phase [352]. this accelerated g1/s transition was accompanied by down-regulation of p27(kip1), a major inhibitor for g1 cyclin-dependent kinases [352]. inactivation of pten in es cells and in embryonic fibroblasts resulted in elevated levels of pip3. consequently, pten deficiency led to dosage-dependent increases in phosphorylation and activation of akt/pkb and akt activation increased bad phosphorylation and promoted pten (-/-) cell survival [352]. fas-mediated apoptosis was impaired in pten (+/-) mice, and t lymphocytes from these mice show reduced activation-induced cell death and increased proliferation upon activation. pi3k inhibitors restored fas responsiveness in pten (+/-) cells [353]. these results indicated that pten is an essential mediator of the fas response and a repressor of autoimmunity and thus implicated pi3k/akt pathway in fas-mediated apoptosis [353].",pmc2652403,1,10,19,1,29
823,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,pi 3-kinase,protein,,pik3ca,uniprot,p42336,cytoplasm,go:0005737,positive,i,phosphorylation,histone acetyltransferase tip60,rat-1,fibroblast,endothelial,rat,['501'],nan,nan,"in this study, we investigated the role of p53 in apoptosis and changes in the program of gene expression resulting from inhibition of pi 3-kinase in otherwise normally proliferating cells. we addressed this question by characterizing the transcriptional response to inhibition of pi 3-kinase in rat-1 cells, which have a normal tp53 gene,31, 32 compared with rat-1 cells expressing a dominant-negative p53 mutant. analysis of apoptosis and gene regulation in these cells indicates that p53 is a major component of the network that contributes to cell survival and alterations in gene expression downstream of pi 3-kinase signaling, along with foxo, mitf and usf1. the principal mechanism leading to activation of p53 in response to inhibition of pi 3-kinase is phosphorylation of the histone acetyltransferase tip60 by gsk3, leading to acetylation and activation of p53. major changes in gene expression and cell survival following inhibition of pi 3-kinase thus result from the activation of p53, mitf and usf1 via gsk3, in addition to the activation of foxos resulting directly from inhibition of akt.",pmc3481126,1,10,19,1,29
800,p53,protein,dominant-negative,tp53,uniprot,p04637,nucleus,go:0005634,pi 3-kinase,protein,,pik3ca,uniprot,p42336,cytoplasm,go:0005737,negative,i,inhibition,,rat-1,fibroblast,,human,['503'],nan,nan,"we investigated the effect of dominant-negative p53 expression on apoptosis in response to inhibition of pi 3-kinase by treating cells with the small-molecule inhibitor, pi-103.36 inhibition of pi-3 kinase rapidly induced apoptosis in both wild-type rat-1 cells and cells expressing dominant-negative p53, as indicated by dna fragmentation as early as 1 h after treating with pi-103 (figure 1c). however, quantification by tunel assays indicated that apoptosis was significantly inhibited in both clones expressing the dominant-negative p53 mutant (figure 1d). these results indicate that p53 contributes to but is not essential for apoptosis in response to inhibition of pi 3-kinase. similar results were obtained following treatment with gdc-0941, which is a more specific pi 3-kinase inhibitor that does not affect mtor or related protein kinases37 (see figure 8).",pmc3481126,1,10,19,1,29
768,nox1,protein,,nox1,uniprot,o75508,plasma membrane,go:0005886,c-src,protein,,src,uniprot,p12931,plasma membrane,go:0005886,positive,d,activation,,,colon cancer cells,colon,human,['1355'],nan,nan,"strong evidence has highlighted the importance of nox1-dependent ros generation in mechanisms of cancer invasion (arnold et al., 2001; mitsushita et al., 2004; kamata, 2009). consistent with this, our group has shown that in human colon cancer cells nox1-derived ros are necessary for the formation of extracellular matrix (ecm)-degrading actin-rich cellular structures known as invadopodia (gianni et al., 2009). invadopodia appear as actin protrusions of the ventral plasma membrane and contain proteases capable of degrading the ecm (linder, 2007; gimona et al., 2008). their formation in human cancer cells correlates with their invasiveness both in vitro and in vivo (weaver, 2006). the tyrosine kinase c-src is highly expressed and active in human colon epithelial tumors (bolen et al., 1987; irby and yeatman, 2000). consistent with this, c-src activation is required for the formation of functional invadopodia (lowe et al., 1993). there is substantial evidence for the importance of c-src in invadopodia formation. many src substrates are obligate invadopodia components, including cortactin, tks4, and tks5 (abram et al., 2003; baldassarre et al., 2003; buschman et al., 2009). interestingly, tks proteins (tyrosine kinase substrate with five or four sh3 domains) have been shown to be required for the formation of invadopodia and to promote cancer cell invasion (seals et al., 2005; blouw et al., 2008; buschman et al., 2009). however, despite much effort, the signals and the molecular machinery involved in the redox-dependent regulation of src-induced invadopodia formation remain unclear.",pmc2993755,1,10,19,1,29
732,mtor,protein,,,uniprot,p42345,cytoplasm,go:0005737,c-src,protein,,src,uniprot,p12931,cell membrane,go:0005886,positive,d,transactivation,,,,,human,['2836'],nan,nan,"the data presented here show that rapamycin, perhaps by inhibiting mtor and its downstream signaling element(s), activates c-src which then transactivates the egfr to stimulate the erk1/2 pathway and increases cell survival. transactivation of the egfr by src kinase has already been reported (tice et al., 1999) and aberrant signaling due to overexpression of egfr has also been shown to play an important role in hyperproliferative diseases (fischer et al., 2003). based on these findings preclinical and clinical data have strongly suggested the potent effect of tyrosine kinase inhibitors as anticancer agents (metro et al., 2006) and egfr family kinase inhibitors such as gefitinib, erlotinib, and lapatinib are already in clinical use or trials. similarly, src kinase inhibitor su6656 (perhaps, in part by inhibiting egfr transactivation) has also been shown to attenuate the activation of ras-erk1/2 and pi-3k/akt cascades (jin et al., 2007) and is currently used in preclinical studies.",pmc2653860,1,10,19,1,29
721,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,vegf,protein,,vegfa,uniprot,p15692,extracellular,go:0005576,positive,i,overexpression,,,cancer,prostate,human,['1980'],nan,nan,"several key proteins are overexpressed as a consequence of mtor activation including: c-myc [397-399], cyclin d1 [399], and vegf [400] and others. cyclin d1 has been reported to be overexpressed in prostate cancer xenografts and metastases [401], while early stage prostatic lesions possess much lower levels of the protein [402]. a number of reports support the notion that mtor signaling is a prominent feature of cancer progression and aging, as recurrent tumors have altered expression of a number of molecular targets of rapamycin including the above mentioned genes which encode “weak” mrnas [403-406]. hence mtor inhibitors such as rapamycin may be effective in cancer therapy.",pmc3660063,1,10,19,1,29
904,protein kinase c (pkc),protein,classical,pkc,uniprot,p17252,plasma membrane,go:0005886,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,positive,i,activation,multiple tyrosine residues,u-1242 mg and u-87 mg,glioblastoma,brain,human,['1409'],nan,nan,"in glioblastoma cell lines u-1242 mg and u-87 mg, phorbol 12-myristate 13-acetate (pma), an activator of protein kinase c (pkc), has been shown to activate egfr, as judged by the phosphorylation of multiple tyrosine residues (including y845) [115]. in this transactivation system for egfr, pkcδ-dependent activation of src, which seems to require pkcδ phosphorylation of src on serine 12 and/or serine 48, takes place. as has been well appreciated, pkc (namely, classical pkcs such as pkcα, βi/βii, γ)-dependent phosphorylation of egfr on t654 promotes endocytic disappearance of the receptor from the cell surface and thus acts as an inhibitory signal to egfr signaling [30,116]. in a431 and human embryonic kidney 293 (hek293) cells, diacylglycerol kinase θ has been shown to counteract such pkc-dependent inactivation of egfr, so that y845 phosphorylation and other signaling events are maintained [117].",pmc3709701,1,10,19,1,29
916,pten,protein,short hairpin rna,pten,uniprot,p60484,cytoplasm,go:0005737,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,i,activation,,bj-t cells,fibroblasts,skin,human,['3344'],nan,nan,"we utilised the well-characterised bj human fibroblasts immortalised with human telomerase reverse transcriptase (bj-t cells) (hahn et al., 1999) as a model to study the mechanisms of pi3k-induced responses in non-transformed human fibroblasts. bj-t cells were transduced with expression constructs encoding pten short hairpin rna (shrna) or the pi3k catalytic subunit mutant pik3cae545k (zhao et al., 2005), which is commonly detected in multiple cancer types and enhances pi3k/akt pathway signalling (campbell et al., 2004; samuels et al., 2005). cells with depleted pten protein levels or expressing pik3cae545k exhibited increased levels of phospho-akt and phosphorylation of the akt substrate pras40 (proline-rich akt substrate of 40 kda) demonstrating pi3k pathway activation and consistent with a previous report (kim et al., 2007) accumulation of cell cycle inhibitors p53 and its target p21 (figure 1a). cells expressing pten shrna or pik3cae545k also exhibited a significant increase in cell size (figure 1b) and senescence-associated β-galactosidase activity (saβgal) (figure 1c). these results indicate that activation of pi3k activity induces multiple markers of senescence in the bj-t human fibroblasts.",pmc3325598,1,10,19,1,29
912,pten,protein,,pten,uniprot,p60484,,,mtor,protein,,mtor,uniprot,p42345,,,positive,i,up-regulates,,,,ovarian and endometrial cancers,human,['1965'],nan,nan,"akt and mtor phosphorylation are frequently detected in ovarian and endometrial cancers. an early occurrence in endometrial cancer is the loss of functional pten activity by mutation or other mechanisms, this occurs in approximately 40-80% of patients [333]. since the loss of pten results in activation of akt, that in turn up-regulates mtor activity, cancer cells deficient in pten are thought to be major targets of mtor inhibitors.",pmc3660063,1,10,19,1,29
705,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,igf1,protein,,igf1,uniprot,p05019,extracellular region,go:0005576,positive,d,activation,,,,,,['606'],nan,nan,"mtor is a central integrator for upstream inputs from growth factors, nutrients and stress [12]. insulin-like growth factor-1 (igf1), for instance, can activate mtorc1 through its receptor tyrosine kinase (rtk)-mediated phosphorylation and activation of pi3k and akt and akt in turn mediates phosphorylation of tuberous sclerosis 2 (tsc2) and proline-rich akt substrate 40 kda (pras40), thus releasing their inhibition of mtorc1 [13,14]. rtks also activate mtorc1 through ras-extracellular signal-regulated kinase (erk) pathway [15] and subsequent erk phosphorylation of the mtorc1 inhibitor tsc2 [16] and raptor [17]. this growth factor-mtorc1 pathway is regulated through two negative feedback loops: mtorc1-p70s6k-mediated phosphorylation and degradation of insulin receptor substrate (irs) [18,19] and mtorc1-mediated phosphorylation of growth factor receptor-bound protein 10 (grb10) [20].",pmc3750018,1,10,19,1,29
918,pten,protein,tumor suppressor,pten,uniprot,p60484,cytoplasm,go:0005737,mdm2,protein,,mdm2,uniprot,q00987,nucleus,go:0005634,negative,i,inhibits,nucleus,,glioblastoma,brain,human,['3636'],nan,nan,"the pten tumor suppressor protein inhibits pi3k/akt signaling that promotes translocation of mdm2 into the nucleus [195, 377]. when restricted to the cytoplasm, mdm2 is degraded [377]. the ability of pten to inhibit the nuclear entry of mdm2 increases the cellular content and transactivation of the p53 tumor suppressor protein. retroviral transduction of pten into pten null glioblastoma cells increases p53 activity and expression of p53 target genes and induces cell cycle arrest [378]. u87mg/pten glioblastoma cells were more sensitive than u87mg/pten null cells to death induced by etoposide, a chemotherapeutic agent that induces dna damage [378]. these results established a direct connection between the activities of two major tumor suppressors and show that they act together to respond to stresses and malignancies. pten protects p53 from survival signals, permitting p53 to function as a guardian of the genome [377, 378].",pmc2652403,1,10,19,1,29
919,pten,protein,tumor suppressor,pten,uniprot,p60484,cytoplasm,go:0005737,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,negative,d,inhibition,,,colon cancer cells,colon,human,['3579'],nan,nan,"pten is commonly mutated in various cancers,40, 41 as it normally functions as a tumor suppressor to antagonize the effects of pi3k through its lipid phosphatase activity. consequently, akt activation is balanced by both pten and pi3k. in the present study, we observed that selenite inhibited the phosphorylation of src and the p85 subunit of pi3k and its downstream effectors pdk1 and akt. additionally, pten expression was upregulated by foxo3a and (figures 2f and 4c), and pten activity was enhanced in response to selenite treatment (figure 4d). these findings are supported by work from meuillet and coworkers.42 therefore, we hypothesized that selenite-induced activation of pten was involved in regulation of the akt/foxo3a/bim signaling pathway. we transfected cells with lipid phosphatase-dead pten plasmids or pten sirna as well as inhibiting pten with sf1670 and discovered that selenite-mediated modulation of the akt/foxo3a/bim pathway was abrogated when pten was inhibited. furthermore, activating pten with nabt in hct116 and sw480 crc cells exerted further inhibitory effects on the akt/foxo3a/bim signaling pathway (supplementary figure s4). we concluded that selenite-induced pten was associated with the akt/foxo3a/bim pathway and apoptosis in hct116 and sw480 crc cells, which is consistent with the findings from other groups showing that pten directly regulates akt/foxo3a under various circumstances.43, 44 however, whether a positive feedback loop exists between pten and the akt/foxo/bim signaling pathway requires further study.",pmc3734838,1,10,19,1,29
928,raf,protein,active,raf1,uniprot,p04049,cytoplasm,go:0005737,erk,protein,active,mapk1,uniprot,p28482,nucleus,go:0005634,positive,i,renders adhesion independent,,,,,,['2765'],nan,nan,expression of active raf or mek1 renders erk activity adhesion independent,pmc2169466,1,10,19,1,29
935,raf-1,protein,,raf1,uniprot,p04049,,,pp2a,protein,,ppta,uniprot,p67775,,,positive,d,dephosphorylation,,,,,,['1927'],nan,nan,"raf-1 can be regulated by dephosphorylation by the protein serine/threonine phosphatase 2a (pp2a) and others [41,42]. pp2a has been reported to positively and negatively regulate raf-1. pp2a is also considered a tumor suppressor gene and has gatekeeper gene functions [43].",pmc3660063,1,10,19,1,29
939,ras,protein,,hras,uniprot,p01112,cytoplasm,go:0005737,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,negative,i,feedback regulation,,,,,human,['2680'],nan,nan,"to analyze the signaling dynamics, we measured experimentally and simulated in silico the time course of activation of ras/erk and pi3k/akt pathways stimulated by step changes in the egf and insulin concentrations. first, cells were stimulated with 100 nm insulin or with several egf concentrations that ranged from low concentrations of 0.1 nm to saturating concentrations of 20 nm (figure 2). both the experimental data and simulations showed that the activation of the ras/erk and pi3k/akt pathways by persistent egf or insulin stimulation was transient (figure 2 and supplementary figure s3). the model explains this transient behavior by multiple negative feedback regulations mediated by erk, akt and mtor. in fact, disruption of negative feedback loops in silico transforms transient ras/erk and pi3k/akt pathway responses into sustained responses (supplementary figure s5).",pmc2683723,1,10,19,1,29
1045,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,nox1,protein,,nox1,uniprot,q9y5s8,cell membrane,go:0005886,positive,i,regulation,,human colon cancer cells,epithelial,colon,human,['1385'],nan,nan,this article describes the signaling events required for src-induced ros-dependent formation of functional invadopodia in human colon cancer cells and implies that src-mediated regulation of the nox1 activity is an important mean of controlling nox1-dependent biological functions. our results suggest the possibility to modulate nox1 function indirectly by pharmacologic intervention using specific and effective src inhibitors well tolerated in vivo.,pmc2993755,1,10,19,1,29
1067,src kinase,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,mek,protein,kinase,map2k1,uniprot,q02750,cytoplasm,go:0005737,negative,i,inhibition,invasion,,mesenchymal,,human,['2082'],nan,nan,"the ‘mesenchymal’ mode of invasion is extremely sensitive to src kinase inhibition (16). therefore, we hypothesised that inhibiting src kinase activities represents a potential strategy to overcome mek-inhibitor effects on invasion.",pmc3378628,1,10,19,1,29
1092,tp53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,pten,protein,,pten,uniprot,p60484,nucleus,go:0005634,negative,i,mutation,,,,,,['1914'],nan,nan,"before we discuss the ras/raf/mek/erk and ras/pi3k/pten/akt/mtor signaling cascades, it is important to define some genetic terms as they are critical to understanding the importance of these pathways and the classes of genes and mutations that occur in components of these cascades. we briefly discuss certain classes of genes which play key roles in the development of cancer. caretaker genes are involved in genomic stability and normally function to suppress the mutation rate [10]. caretaker mutations occur mainly in tumor suppressor genes, such as tp53 (p53) and pten. tp53 and pten are caretaker genes. caretaker genes help maintain the integrity of the genome.",pmc3660063,1,10,19,1,29
1098,tsc2,protein,,tsc2,uniprot,p49815,cytoplasm,go:0005737,igf1-r,protein,,igf1r,uniprot,p08069,plasma membrane,go:0005886,positive,i,protein levels,,,,,,['682'],nan,nan,"−/− mef line in which wild-type tsc2 has been reintroduced (−/− +wt). aliquots of these samples were run on a separate gel and probed for β-actin as a control for rna content (bottom). white line indicates that intervening lanes have been removed. (c) irs-1 (first panel), irs-2 (second panel), inr (third panel), and igf1-r (fourth panel) protein levels in tsc2",pmc2172316,1,10,19,1,29
1099,tsc2,protein,,tsc2,uniprot,p49815,cytoplasm,go:0005737,irs-1,protein,,irs1,uniprot,p35568,cytoplasm,go:0005737,negative,i,phosphorylation,λ-phosphatase,,mefs,,,['691'],nan,nan,−/− mefs exhibit reduced migration on sds-page gels (fig. 2 c). treatment of irs-1 immunoprecipitates with λ-phosphatase indicates that the reduced migration of irs-1 in tsc2,pmc2172316,1,10,19,1,29
1105,tsc2,protein,,tsc2,uniprot,p49815,,,irs-1,protein,,irs1,uniprot,p35568,,,negative,i,phosphorylation,,mefs,,,,['694'],nan,nan,"−/− mefs for various times with rapamycin followed by immunoblotting for irs-1 (top) or irs-2 (bottom). the slower migrating, more heavily phosphorylated irs-1 or irs-2 present in tsc2",pmc2172316,1,10,19,1,29
1106,tsc2,protein,,tsc2,uniprot,p49815,,,irs-1,protein,,irs1,uniprot,p35568,,,negative,i,reduce abundance of mrna,,mefs,,,,['679'],nan,nan,"−/− mefs (fig. 2 a). to confirm this result, we analyzed irs-1 mrna. irs-1 mrna abundance is significantly reduced in tsc2",pmc2172316,1,10,19,1,29
707,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,lkb1,protein,tumor suppressor,stk11,uniprot,q15831,cytoplasm,go:0005737,positive,i,activates,,,,,human,['1452'],nan,nan,"activated mtor pathway is also related to various familial cancer syndromes. the loss of tumor suppressor lkb1 (liver kinase b1), which is a key kinase for activating ampk [152], results in pentz-jeghers syndrome [153]. mutations in tsc1 or tsc2 cause tuberosis sclerosis [154], another familial cancer syndrome, and pten mutations result in cowden's syndrome [155]. these syndromes result in benign tumors which may progress to malignancies.",pmc4258317,1,10,19,1,29
677,mtor,protein,kinase,mtor,uniprot,p42345,cytoplasm,go:0005737,egfr,protein,receptor,egfr,uniprot,p00533,plasma membrane,go:0005886,positive,i,increase of phosphorylation,,,colorectal carcinoma,xenografts,human,['609'],nan,nan,"to examine the therapeutic potential of the mtor kinase inhibitor pp242, we show here that pp242 can only transiently block the mtorc2 kinase activity in the first few hours of the treatment. in parallel, the return of mtorc2 kinase activity is associated with the increase of phosphorylated egfr. the combination treatment of pp242 and erlotinib, an egfr inhibitor, completely block both mtorc1 and mtorc2 activity, inhibits cell growth and suppresses the progression of colorectal carcinoma xenografts.",pmc3750018,1,10,19,1,29
104,akt,protein,,,uniprot,p31749,cytoplasm,go:0005737,caspase-9,protein,,casp9,uniprot,p55211,cytoplasm,go:0005737,negative,i,inhibition,postmitochondrial level,,b-cell,,human,['1611'],nan,nan,"to confirm that expressing active akt inhibits the apoptotic cascade downstream of cytochrome c release, a cell-free system was used to examine parp cleavage and caspase-3 activation. in extracts prepared from vector-transfected cells, parp was rapidly cleaved. after a 15-min incubation with cytochrome c and datp, only a small fraction of intact parp remained and, by 30 min, all intact parp disappeared (fig. 7 a). in contrast, in extracts prepared from akt stable cell lines, cytochrome c–induced parp cleavage was markedly inhibited and delayed. the cleaved parp fragment was detectable only after 60–90 min and a large percentage of intact parp was still present after 120 min (fig. 7 a). these data confirm that active akt inhibits caspase activation downstream of cytochrome c. on the other hand, parp cleavage induced by cytochrome c in extracts prepared from bcl-2–stable lines proceeded similarly to cleavage in vector-control cell extracts (fig. 7 b). taken together, these cell-free studies suggest that akt can regulate apoptosis at a postmitochondrial level, whereas bcl-2 regulates apoptosis primarily at the mitochondrial level. using an antibody that recognizes cleaved/activated caspase-3, we further analyzed caspase-3 processing induced by cytochrome c in the cell-free assay. consistent with results for parp cleavage, caspase-3 cleavage/activation was also inhibited in extracts prepared from akt-stable lines compared with caspase-3 cleavage/activation in vector-control cell extracts (fig. 7 c). since caspase-9 is the initiator caspase for cleaving and activating caspase-3, we examined whether caspase-9 activation by cytochrome c and datp was inhibited in extracts prepared from akt-stable lines (fig. 7 d). caspase-9 activity assays showed that activation of caspase-9 by cytochrome c and datp was inhibited in extracts prepared from akt-stable lines compared with those in vector-control cell extracts, indicating that expressing active akt effectively inhibits the cytochrome c–initiated caspase activation cascade.",pmc2185587,1,10,19,1,29
672,mtor,protein,kinase,frap1,uniprot,p42345,cytoplasm,go:0005737,irs,protein,adapter,irs1,uniprot,p35568,cytoplasm,go:0005737,positive,i,feedback regulation,,,,,human,['957'],nan,nan,"it has been reported that mek and mtor inhibitors induce increased levels of phospho-akt via negative feedback regulation of irs (wan et al, 2007; jiang et al, 2009). as expected, mek and mtor inhibitors induced increased levels of pakt and irs-1, an outcome that limits their clinical anticancer efficacy; importantly, co-treatment with α-tea was able to block this counterproductive increase in these potent prosurvival mediators (figure 5g).",pmc3039802,1,10,19,1,29
124,akt,protein,serine/threonine kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,pi3k,protein,phosphoinositide-3-kinase,pik3ca,uniprot,p42336,plasma membrane,go:0005886,positive,i,activation,cytoplasm,,lung cancer cells,lung,human,['412'],nan,nan,"evasion of apoptosis by tumor cells is a critical step during tumorigenesis. the serine/threonine kinase akt is a critical mediator of anti-apoptotic signaling in eukaryotic cells and is activated in a signaling cascade downstream of ras activation and phosphoinositide-3-kinase (pi3k) [2]. amplification of pi3k is common in many tumor types, including lung cancer [3-5] and in lung cancer is correlated with increased phosphorylation of akt [4]. activation of akt, as measured by phosphorylation of the protein, is also increased in multiple tumor types including lung cancer [6-10]. increased phosphorylation of akt kinase has also been reported in developing bronchial hyperplasias and dysplasias [7,11,12] and pre-neoplastic atypical alveolar hyperplasia [13], indicating that activation of this pro-survival pathway may be a relatively early event in lung tumorigenesis.",pmc1325242,1,10,19,1,29
125,akt,protein,serine/threonine kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,pten,protein,lipid phosphatase,pten,uniprot,p60484,plasma membrane,go:0005886,positive,i,activation,,,,lung,human,['424'],nan,nan,"the serine/threonine kinase akt is a central mediator of anti-apoptotic pathways in eukaryotic cells [2]. activation of this kinase occurs when it is itself activated by pi3k-dependent protein kinase 1 or 2 (pdk1 or 2). previous studies have noted an increase in the amount of phosphorylated akt in a number of different human malignancies including cancer of the lung [4,7,12], head and neck [46], prostate [9], and in multiple myeloma [8,47]. in addition, loss of the tumor suppressor phosphatase and tensin homologue (pten), a lipid phosphatase that inhibits pi3k activity, is found in a subset of lung tumors [48-50]. increased staining for phosphorylated akt was also frequently observed in human bronchial pre-neoplastic lesions [4,7,12]. in bronchial ien, increased staining for phospho-akt correlated with increased staining for phospho-fkhr, a transcription factor that directs expression of anti-apoptotic genes in response to akt signaling [7]. our present results agree with previous studies demonstrating an increase in phospho-akt staining in pre-neoplastic human bronchial lesions. we observed increased staining for the phosphorylated form of akt beginning as early as mild dysplasia lesions in human bronchial biopsies.",pmc1325242,1,10,19,1,29
175,b-raf,protein,kinase,braf,uniprot,p15056,cytoplasm,go:0005737,mtor,protein,kinase,mtor,uniprot,p42345,cytoplasm,go:0005737,negative,i,inhibition,,human melanoma cells,melanoma,skin,human,['2443'],nan,nan,synergistic inhibition of human melanoma proliferation by combination treatment with b-raf inhibitor bay43-9006 and mtor inhibitor rapamycin,pmc1289294,1,10,19,1,29
178,b-raf v599e mutants,protein,mutant,braf,uniprot,p15056,plasma membrane,go:0005886,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,positive,i,inhibition,,melanoma,melanoma,skin,human,['2450'],nan,nan,"our interest is in combining targeted agents for these pathways in an effort to determine if such treatments will be effective in the treatment of melanoma. we hypothesized that the combination of multiple targeted therapeutic agents would result in enhanced inhibition of melanoma cell proliferation compared to either drug alone, because of synergy between effects on two pathways. here we show that serum-stimulated melanoma cell proliferation is inhibited by either rapamycin or bay43-9006, with b-raf v599e mutants showing an increased sensitivity to each drug at 10 nm compared to melanoma cells with wild-type b-raf. each of these drugs inhibited the serum-stimulated phosphorylation of known raf and mtor substrates. what was unexpected was that each of the drugs inhibited phosphorylation in both the raf and mtor pathways, suggesting there was interdependence or cross-talk between these pathways in melanoma cells. furthermore, the combination of rapamycin with bay43-9006 was synergistic compared to either drug alone at inhibiting proliferation of wild-type b-raf and v599e mutant b-raf melanoma cell lines.",pmc1289294,1,10,19,1,29
185,bcl-2,protein,,bcl2,uniprot,p10415,,,cyclin d1,protein,,ccnd1,uniprot,p24385,,,positive,d,reduction,,,adenocarcinoma,kras-mutated,,['2356'],nan,nan,"the downregulation of bcl-2 is thought to be one of the important modes of apoptosis induced by treatment with taxanes.46 we observed that paclitaxel induces apoptosis, even in the absence of the reduction in bcl-2 expression, suggesting that it may be attributed to the lower concentration of paclitaxel.47 our experiment demonstrated that cink4 alone did not reduce bcl-2 expression, but when combined with paclitaxel, bcl-2 expression was significantly reduced. paclitaxel alone did not reduce cyclin d1, but greatly reduced it when combined with cink4. our results suggest both bcl-2 and cyclin d1 are important molecules for synergistic anti-proliferative activity when paclitaxel is combined with cink4. we propose that downregulation of cyclin d1 by cink4 may enhance sensitivity to paclitaxel, subsequently leading to increased apoptosis in kras-mutated adenocarcinoma cells.",pmc3742489,1,10,19,1,29
312,chk2,protein,,chek2,uniprot,o96017,,,pp2a,protein,,ppa2,uniprot,p30153,,,positive,d,binding,,,,,human,['1672'],nan,nan,"in humans, chk2 was found to be regulated by pp2a and wip1. inhibition of pp2a using okadaic acid increased the phosphorylation of chk2. although pp2a was also found to negatively regulate atm, the effect on chk2 phosphorylation was atm-independent [103]. utilizing a yeast two-hybrid system, an in vitro binding assay, and co-immunoprecipitation, chk2 was found to bind to pp2a a, c, and many b' subunits. chk2 was able to phosphorylate b'γ1 and b'γ3 in vitro and this increased pp2a activity in vitro. the overexpression of b'γ3 resulted in a decrease in chk2 phosphorylation after doxorubicin treatment, which causes dna adducts [124]. following cisplatin treatment, pp2a containing a b subunit was found to bind to chk2. inhibition of pp2a with okadaic acid or knockdown via sirna caused an increase in chk2 phosphorylation at t68. pp2a was found to dephosphorylate chk2 in vitro as well [125].",pmc2954851,1,10,19,1,29
359,cyclin d1,protein,,ccnd1,uniprot,p24385,,,rela,protein,,rela,uniprot,q04206,nucleus,go:0005634,positive,i,stimulation,nucleus,,lung,,human,['2355'],nan,nan,"alterations in the expression of genes that control the cell cycle may be of critical importance in determining drug sensitivity to anti-cancer agents. cyclin d1 has been proposed as a chemoprevention target and a surrogate marker of chemopreventive response in lung cancer.38,39 targeting of cyclin d1 suppresses tumor growth via cell cycle arrest and promotes tumor apoptosis in nsclc.40-42 inhibition of cyclin d1 leads to cellular apoptosis through stimulation of the nfκb pathway with nucleolar translocation of rela.43,44 basseres et al. showed that deletion of rela reduced the number of kras-mutant induced lung tumors with a higher number of apoptotic cells.45 therefore, our results suggest cyclin d1 plays a key role in apoptotic induction by cink4 treatment in kras-mutated lung cancer.",pmc3742489,1,10,19,1,29
373,e2f1,protein,,e2f1,uniprot,q01094,,,sp1,protein,,sp1,uniprot,p08047,,,positive,d,transfected,,,,,,['331'],nan,nan,"the e2f1 luciferase reporter plasmid under the control of 4 e2f1 consensus and negative control sp1 plasmids as a 3x × sp1 consensus were transfected in galectin-3-depleted or galectin-3-overexpressing cells using the lipofectamine 2000 reagent (invitrogen) as described previously.42 after 30–40 h, the cells were harvested and the luciferase activity was estimated using a luciferase assay system (promega). the results were normalized to β-galactosidase.",pmc4211374,1,10,19,1,29
382,egf receptor (egfr),protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,igf-1 receptor,protein,,igf1r,uniprot,p08069,plasma membrane,go:0005886,positive,d,hetero-dimerization,,,,lung,human,['2980'],nan,nan,"in lung cancer therapy, anti-angiogenic or anti-inflammatory agents show widespread efficacy across many cancer types, while inhibition of the egf receptor (egfr) is mainly effective in the nsclc sub-population containing activating egfr mutations [40,47]. egfr-mutant lung cancers eventually become resistant to anti-egfr therapies, and then progress rapidly [12,40]. one proposed mechanism for lung cancer resistance to anti-egfr therapy is the increased expression of other egfr family receptors and/or the igf-1 receptor [48]. similar to the well-described hetero-dimerization among the egf receptor family, igf-1r can form functional complexes with egfr [12,48]. unlike igf-1r, egfr can be stimulated by numerous egf-like factors, which macrophages produce in a tissue and disease-specific manner [10,14,49]. however, we show that: 1) balf egf levels are very low and do not differ between naïve and tumor-bearing lungs; 2) macrophages produce trace amounts of egf in vitro; and 3) egf does not stimulate neoplastic lung proliferation either alone or in combination with igf-1 or møcm (figures 6, 7 and data not shown). combined, these observations indicate that egf is not involved in the macrophage-stimulation of pulmonary epithelial growth in vitro, and argue against significant lung macrophage egf production in vivo. the increased egfr phosphorylation in primary mouse lung tumors bearing kras mutations that we previously reported could result from igf-1r/egfr coupling and trans-activation after igf-1 stimulation [48,50]. mutations in egfr and kras are mutually exclusive in both human and murine nsclc, and egf stimulation would not be expected drive kras mutant models of lung cancer [23,40,50]. a requirement for the igf-1 receptor in mediating lung cancer growth is consistent with other reports that igf-1 stimulates rapid anchorage-independent growth in vitro, while igf-1r inhibition slows tumor growth in both animal xenograft studies [27] and human clinical trials [12].",pmc3135566,1,10,19,1,29
385,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,ir,protein,,insr,uniprot,p06213,plasma membrane,go:0005886,positive,i,synergistic activation,,hek293 cells,,,human,['2675'],nan,nan,"although many mechanisms of egfr–ir crosstalk are well characterized at the molecular level, this knowledge is insufficient to understand cellular responses to egf plus insulin at the systems level, owing to the multitude of interpathway interactions and feedback loops. this paper brings together experimental studies of combined egf and insulin signaling with computational modeling of the interactive egfr and ir networks. we show that, although in hek293 cells insulin by itself is a poor activator of erk, it greatly enhances mapk pathway activation by physiological egf concentrations. the computational model elucidates the function of feedback loops and crosstalk nodes in combined egf and insulin signaling. we demonstrate that synergistic activation of the mitogenic pathway by egf plus insulin primarily occurs upstream of and at the ras/raf level. this potentiation of ras/erk response is initiated by insulin-induced pip3 increase, which leads to subsequent increases in membrane recruitment of grb2–sos and shp2 by gab1 and irs. the computational model unveils that insulin makes the mitogenic egfr signal more robust toward gab1 knockdown. our results may have important ramifications for the identification of therapeutic targets aimed at eliminating insulin-induced amplification of mitogenic and survival signaling stimulated by low growth factor levels in tumor cells.",pmc2683723,1,10,19,1,29
386,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,mtor,protein,kinase,mtor,uniprot,p42345,cytoplasm,go:0005737,negative,i,inhibition,,colorectal carcinoma,epithelial,colon,human,['623'],nan,nan,"next, we thought to examine the biological effects of the combination of egfr and mtor inhibitors on colorectal carcinoma cells. to this end, we treated the carcinoma cell lines with erlotinib (2 μm) and pp242 (0.5 μm), alone and in combination, for 24 hours in the presence of egf (50 ng/ml) according to the experimental design as described in figure 2. cell viability assay revealed that the combination treatment produced a significant synergy in the cell growth inhibition (figure 3b). to examine this further, we treated the cells for 14 days in a colony formation assay and showed that the combination treatment synergistically eliminated the formation of colonies from each of these cell lines (figure 3b, c). collectively, these results suggest that the combination of pp242 and erlotinib completely blocks both mtorc1 and mtorc2 kinase activity and synergistically inhibits the growth of colorectal carcinoma cells.",pmc3750018,1,10,19,1,29
387,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,positive,i,inhibition,,,mixed,,human,['898'],nan,nan,"rapamycin analogues are also being tested in combination with egfr or her-2 inhibitors. early trials of egfr inhibitors combined with analogues in glioblastoma patients did not disclose any positive results and lung cancer patients resistant to egfr inhibitors showed toxic effects that required discontinuation or dose reductions in some patients [216,217]. trials combining hormonal therapies with mtor inhibitors are been performed in breast cancer, since resistance to hormonal therapy has been associated with overactivation of the mtor pathway [218]. phase i/ii trials with trastuzumab combined with everolimus in her-2+ metastatic breast cancer that progressed on trastuzumab therapy reported clinical benefit and restore trastuzumab sensitivity [219]. phase i and ii trials of mtor inhibitors in combination with erlotinib, gefitinib or cetuximab are ongoing.",pmc3291999,1,10,19,1,29
391,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,positive,d,phosphorylation,y845,a431 epidermoid carcinoma cells,epithelial,skin,human,['1393'],nan,nan,"intracellular communication between egfr and src, which contributes to cancer malignancy, was first demonstrated in the late 1980s. parsons and others showed that egf-dependent protein-tyrosine phosphorylation and mitogenic cell responses are augmented in cells overexpressing src [16,37,38]. at this time, however, phosphorylation of y845 by src was unknown. later, wasilenko et al. [39] made the first demonstration that src is capable of phosphorylating egfr on unknown tyrosine residue(s). in this work, trypsin-digested phosphopeptides were analyzed in cells expressing both egfr and src, and thus the identification of phosphorylated y845 was not made. the first evidence showing that src directly phosphorylates egfr on y845 was provided by our work [19], where in vitro phosphorylated egfr in the presence of src was analyzed by tryptic digestion and two-dimensional electrophoresis, by which the identities of egfr-derived phosphopeptides and a synthetic peptide containing phosphorylated y845 were evaluated. in addition, we showed that y845 phosphorylation also occurs in a431 epidermoid carcinoma cells, where a fraction of egfr and src constitutes a physical complex via the activation segment of src [19,40] that we called the inter-dfg-ape region [33,41]. at almost the same time, parsons and others demonstrated that phosphopeptide maps, analyzed after preparation from c3h10t1/2 murine fibroblast-derived 5h cells overexpressing src, contain an src-dependent phosphopeptide that is suggested to contain y845 [42]. later, the same group showed that egfr is phosphorylated on y845 and y1101 in 5h cells [20]. stover et al. also showed that egfr is phosphorylated on two novel tyrosine residues in dld-1 colorectal cancer cells and mcf-7 breast cancer cells: in this case, y891 and y920, but not y845, were identified [27]. these studies suggest that egfr and src communicate with each other by src-dependent phosphorylation of novel tyrosine residues (for review, see [4,43–46]).",pmc3709701,1,10,19,1,29
392,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,src,protein,,src,uniprot,p12931,plasma membrane,go:0005886,positive,d,phosphorylation,y845,breast cancer cells,,breast cancer,human,['1396'],nan,nan,"subsequent studies using breast cancer and other types of human cancer cells demonstrated that the signal transducer and activator of transcription protein (stat) is a possible mediator of the y845 phosphorylation-dependent synergism of egfr and src [47–49]. in breast cancer cells, stat5b was identified as a prominently tyrosine-phosphorylated protein and that expression of the y845f mutant of egfr has an inhibitory effect on this event [47]. the importance of stat5b is further demonstrated by the fact that the tyrosine phosphorylation-defective mutant of stat5b is inhibitory to dna synthesis and proliferation in cells expressing egfr and src [47,50,51]. on the other hand, stat1 and 3, but not stat5b, have been identified as tyrosine-phosphorylated proteins in egf-stimulated a431 cells [49], in which the physical interaction of egfr and src involving y845 phosphorylation has been demonstrated [19,40,48,52]. in this system, it has been shown that high concentrations of egf or the expression of the shc adaptor protein p52/p66, a direct regulator of the src activity [48,53], promote cell cycle arrest and apoptosis, which is accompanied by the induction of p21waf1[54,55]. the application of a src-specific inhibitor pp2 or an anti-y845 phospho-specific antibody into the cells results in decreases in the egf-dependent phosphorylation of stat1/3 and in the extent of p21waf1 induction [49], suggesting that src-dependent y845 phosphorylation serves as a pro-apoptotic signal in this system.",pmc3709701,1,10,19,1,29
398,egfr,protein,receptor,egfr,uniprot,p00533,plasma membrane,go:0005886,c-src,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,positive,i,transactivation,"tyrosine residues 845, 1101","cos7, sw13, b82l",various,various,human,['2834'],nan,nan,"the egfr can be transactivated either by enhanced “inside-out signaling” that would increase cell surface shedding of egfr ligands such as pro hb-egf by stimulating metalloproteinases of the adam (a disintegrin and metalloproteinase) family (asakura et al., 2002; gschwind et al., 2003; prenzel et al., 1999) or by intracellular activation of non-receptor tyrosine kinase c-src (daub et al., 1997), which phosphorylates the egfr on tyrosine residue 845 and 1101 and results in receptor activation (tice et al., 1999). to distinguish between these two mechanisms in rapamycin- induced egfr transactivation, first we determined the role of adams and egfr ligand shedding. while the egfr monoclonal antibody 528 (mab 528) that binds to the extracellular ligand binding domain of the egfr markedly reduced the ability of egf to autophosphorylate the egfr, rapamycin- mediated phosphorylation of the egfr was not altered (supplementary data fig. s3a). additionally, the inhibitors of adams gm6001 and tapi-2 did not alter the ability of rapamycin to transactivate the egfr (supplementary data fig. s3b and s3c). these data suggest that rapamycin does not transactivate the egfr by augmenting the extracellular shedding of its ligand(s). therefore, next we determined the role of c-src in rapamycin- mediated transactivation of egfr. evidence that c-src may be involved in egfr transactivation was provided by our findings in cos7 (supplementary data fig. s4a), sw13 and b82l cells (figs. 5a–5c) where rapamycin increased phosphorylation of egfr on y845, the c-src site (tice et al., 1999). this notion was further validated by the findings that the amount of active c-src (psrc y416) increased (fig. 5a, 5b, and 5d) while the amount of inactive c-src (psrc y527) decreased (fig. 5a) upon rapamycin treatment. to further confirm the role of c-src in the transactivation of egfr we tested the ability of the c-src kinase inhibitor pp2 to attenuate rapamycin- mediated transactivation of the egfr. in control sw13 cells treated with the inactive analog of the csrc inhibitor, pp3, rapamycin increased phosphorylation of the egfr at y845 (fig. 5b). this increase in the receptor phosphorylation was significantly reduced by treatment of the cells with the c-src specific inhibitor pp2. further, pp2, but not the inactive analog, pp3, by inhibiting the egfr phosphorylation obliterated the ability of rapamycin to increase erk1/2 or rsk phosphorylation (fig. 5b and 5c). that pp2 inhibited src activity is evident by the inhibition of phosphorylation of the src on y416 (fig. 5b). similar results with pp2 were also observed in b82l cells (fig. 5c), cos7 cell (supplementary data, fig. s4b) and with another c-src inhibitor, dasatinib (supplementary data fig. s4c). the observation that the c-src kinase inhibitor pp2 inhibits rapamycin- elicited egfr phosphorylation suggests that c-src is upstream of the egfr. this notion was directly tested using b82l cells expressing a form of the egfr that is mutated at the c-src phosphorylation site (y845f). as shown in figure 5d, although rapamycin activated c-src as evident by the increase in amount of psrc y416, it did not increase phosphorylation of either the egfr or its downstream kinases erk1/2 and rsk (fig. 5d). consistent with the notion that csrc is upstream of the egfr, our findings also show that although the egfr kinase inhibitor ag1478, inhibited egfr autophosphorylation on y1173 (not shown) and erk1/2 as well as rsk activation (fig. 5e), the activation of c-src by rapamycin was not altered (fig. 5e); these data also demonstrate that ag1478 did not inhibit c-src activity. interestingly, although c-src activation was not altered by ag1478, the phosphorylation of y845 on the activation segment of the egfr was inhibited (fig. 5e). a previous study has also shown that ag1478 inhibits the ability of c-src to phosphorylate the egfr on y845 (kiley & chevalier, 2007). ag1478, by binding the atp site on egfr, has also been reported to cause dimerization of the inactive egfr (arteaga et al., 1997). thus, it is possible that ag1478 induced dimerization of the inactive receptor and alterations in its structure preclude c-src- mediated phosphorylation of y845 in the activation segment of the egfr.",pmc2653860,1,10,19,1,29
399,egfr,protein,receptor,egfr,uniprot,p00533,plasma membrane,go:0005886,ir,protein,receptor,insr,uniprot,p06213,plasma membrane,go:0005886,positive,d,kinase activity,tyrosine,,,,human,['2671'],nan,nan,"cells respond to a myriad of external cues using a limited number of signaling pathways that convert multiple inputs into diverse cellular decisions. although individual receptors and pathways have been extensively studied, it is not understood how signaling networks integrate multiple cues. the epidermal growth factor (egf) receptor (egfr) and the insulin receptor (ir) belong to the family of receptors with intrinsic tyrosine kinase activity (referred to as receptor tyrosine kinases, rtks), which regulate pivotal cellular processes, including proliferation, differentiation, cell metabolism, survival, and apoptosis (schlessinger, 2000; taniguchi et al, 2006). the main physiological function of insulin signaling is metabolic, involving the control of glucose metabolism and stimulation of protein and lipid syntheses, whereas egf induces proliferative responses.",pmc2683723,1,10,19,1,29
401,egfr,protein,receptor,egfr,uniprot,p00533,plasma membrane,go:0005886,src,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,positive,d,phosphorylation,y845,cancer cells,various,various,human,['1394'],nan,nan,2.1. cooperation of egfr and src in cancer cells involving y845 phosphorylation,pmc3709701,1,10,19,1,29
417,epidermal growth factor receptor (egfr),protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,mammalian target of rapamycin (mtor),protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,positive,i,activation,,,lung cancer cells,lung,human,['733'],nan,nan,"k-ras, lkb1 and epidermal growth factor receptor (egfr) are frequently mutated in non-small cell lung cancer (nsclc). these mutations result in aberrant activation of the phosphoinositide 3-kinase (pi3k)/akt/mammalian target of rapamycin (mtor) signaling pathway [1], [2], [3]. therefore, the pi3k/akt/mtor signaling pathway has emerged as a promising therapeutic target for nsclc.",pmc3114848,1,10,19,1,29
418,erbb2,protein,,erbb2,uniprot,p04626,cell membrane,go:0005886,pten,protein,,pten,uniprot,p60484,cytoplasm,go:0005737,positive,i,activation,,,breast cancer,,human,['3634'],nan,nan,"the erbb2-targeting antibody, trastuzumab (herceptin), has remarkable therapeutic efficacy in certain patients with erbb2-overexpressing tumors. the overall trastuzumab response rate for reasons that are not completely understood. it was reported that pten activation contributes to trastuzumab's antitumor activity. reducing pten in breast cancer cells by antisense oligonucleotides conferred trastuzumab resistance in vitro and in vivo [375]. patients with pten-deficient breast cancers had significantly poorer responses to trastuzumab-based therapy than those with normal pten [375]. additionally, pi3k inhibitors rescued pten loss-induced trastuzumab resistance [375]. thus, pten deficiency was proposed to be a predictor for trastuzumab resistance [375].",pmc2652403,1,10,19,1,29
440,erk,protein,,,uniprot,p27361,cytoplasm,go:0005737,mtor,protein,,mtor,uniprot,o75385,cytoplasm,go:0005737,negative,i,inhibition,,hela,epithelial,cervix,human,['2872'],nan,nan,"effect of erk, proteasome and transcriptional inhibition on mtor inhibition-mediated tfeb activation. a hela cells were treated with fresh fm supplemented with u0126 (10 μm) alone or in co-treatment with torin1 (2 μm), or subjected to nutrient deprivation (nd) alone or in combination with u0126. following immunostaining for tfeb and labeling of nuclei with hoechst 33342 cells were analyzed by multispectral imaging cytometry. for visualization, the data for fm supplemented with u0126 is included both for torin1 (left) and for nd (right) treatments. bars report mean subpopulation distributions among three independent experiments ± sd. statistical significance was tested based on the “active” subpopulation vs. non-treated control (nt), unless otherwise indicated by horizontal lines (student’s two-tailed t-test; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; n.s., p > 0.05). b mean population response of tfeb concentration in hela cells treated as in (a), shown relative to the non-treated levels (nt). unless indicated by horizontal lines, statistical significance was tested vs. non-treated control, nt (student’s two-tailed t-test; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; n.s., p > 0.05). c mean population response of tfeb concentration (relative to the non-treated levels, nt) in hela cells treated with epox (1 μm), actd (1 μg/ml) or vehicle control (dmso) alone or in combination with torin1 (2 μm). bars report the mean among four independent experiments ± sd. statistical significances were tested with student’s two-tailed t-test (*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; n.s., non-significant). d mean population response of tfeb subcellular localization and subpopulation distributions for hela cells treated as in (c). bars report the mean among four independent experiments ± sd. statistical significances were tested with student’s two-tailed t-test (**, p ≤ 0.01; ***, p ≤ 0.001; n.s., non-significant). subpopulations were compared based on the “active” phenotype. e mean tfeb concentration for the three activation phenotypes in a subset of cells treated with torin1 alone or in co-treatment with epoxomicin, as indicated in (c). bars represent the mean among all cells in each cluster for the indicated treatments ± sd",pmc4896000,1,10,19,1,29
451,erk1/2,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,egfr,protein,receptor,egfr,uniprot,p00533,plasma membrane,go:0005886,positive,i,phosphorylated,cytoplasm,,nsclc,lung,human,['494'],nan,nan,"to our knowledge, only a few studies published to date provide data on the clinical outcome of patients with activated erk1/2. in breast cancer patients, phosphorylated erk1/2 (as determined by immunohistochemistry) may predict a poor response to hormonal therapy and, in a subset of patients, a worse survival (mueller et al, 2000; gee et al, 2001). in sclc, and regarding cytoplasmic staining of phospho-erk1/2, the activation of this mapk positively correlates with survival. in our work, we have seen a strong correlation of activated erk1/2 with some clinicopathological variables. in particular, we have demonstrated that there is a strong correlation between positive nuclear and cytoplasmic staining for p-erk and more aggressive tumours (i.e. advanced stage tumours (iii and iv), tumours with hilar or mediastinal lymph node metastases, and tumours with higher t stage), and also between cytoplasmic staining and the grade of differentiation. with regard to survival, although we have seen in invariable analysis that p-erk cytoplasmic expression may predict poor survival, multivariate analysis did not confirm that cytoplasmic erk activation could be used as an independent prognostic factor. this may be due to the strong association of p-erk with advanced stage tumours, metastatic tumours and tumours with higher t stage. in nsclc, a recent report on the expression of egfr and downstream-activated signalling factors activated by this receptor (mukohara et al, 2003) showed that p-erk is activated in about one-third of nsclc, as we report in the present study in a much larger series. in contrast to our data, they found no correlation of the activation of this mapk with clinicopathological variables. another difference in our results with respect to those published by mukohara et al (2003) is that we have almost the double number of patients (n=111 vs n=60). this gives more statistical support and confidence to the results obtained in this study. besides, we have used an antibody that is different from the one used by mukohara's group. we have validated the specificity of the antibody by specific experiments and by its utilisation in other studies by previous authors (sivaraman et al, 1997; mandell et al, 1998; albanell et al, 2001; adeyinka et al, 2002; cohen et al, 2002). these two differences may explain the divergent results between our studies in relation to phospho-erk and its correlation with clinicopathological variables.",pmc2409626,1,10,19,1,29
582,igf-1,protein,,igf1,uniprot,p05019,extracellular,go:0005576,tsc2,protein,,tsc2,uniprot,p49815,cytoplasm,go:0005737,positive,i,provides pro-survival signal,,mef,fibroblast,,mouse,['722'],nan,nan,"−/− mef survival, decreasing basal survival in the absence of igf-1 while increasing survival in the presence of igf-1 (fig. 7, c and d). we conclude that under the conditions of serum withdrawal, igf-1 does not activate pro-survival signaling in tsc2-deficient cells, and that a weaker pro-survival signal is instead provided by mtor/s6k signaling.",pmc2172316,1,10,19,1,29
597,insulin,protein,,ins,uniprot,p01308,extracellular region,go:0005576,erk,protein,,,uniprot,p27361,nucleus,go:0005634,positive,i,amplification,upstream of ras and at the ras/raf level,hek293,epithelial,kidney,human,['2670'],nan,nan,"crosstalk mechanisms have not been studied as thoroughly as individual signaling pathways. we exploit experimental and computational approaches to reveal how a concordant interplay between the insulin and epidermal growth factor (egf) signaling networks can potentiate mitogenic signaling. in hek293 cells, insulin is a poor activator of the ras/erk (extracellular signal-regulated kinase) cascade, yet it enhances erk activation by low egf doses. we find that major crosstalk mechanisms that amplify erk signaling are localized upstream of ras and at the ras/raf level. computational modeling unveils how critical network nodes, the adaptor proteins gab1 and insulin receptor substrate (irs), src kinase, and phosphatase shp2, convert insulin-induced increase in the phosphatidylinositol-3,4,5-triphosphate (pip3) concentration into enhanced ras/erk activity. the model predicts and experiments confirm that insulin-induced amplification of mitogenic signaling is abolished by disrupting pip3-mediated positive feedback via gab1 and irs. we demonstrate that gab1 behaves as a non-linear amplifier of mitogenic responses and insulin endows egf signaling with robustness to gab1 suppression. our results show the feasibility of using computational models to identify key target combinations and predict complex cellular responses to a mixture of external cues.",pmc2683723,1,10,19,1,29
598,insulin,protein,,,uniprot,p01308,extracellular region,go:0005576,pkb/akt,protein,,,uniprot,p31749,cytoplasm,go:0005737,positive,i,promotion,,,,,,['723'],nan,nan,"the insulin–pi3k pathway controls cell number (through promoting cell cycle progression and survival via pkb/akt; lawlor and alessi, 2001) and cell growth (via activation of the s6ks; dufner and thomas, 1999). how, then, do cells and tissues coordinate these activities, given that different relative amounts of cells and growth may normally be required to obtain a given organ size, or to modulate this size during development or in the adult? regulators of coordination may be inferred from human pathologic overgrowth conditions in which such coordination is lost, or in model organisms such as drosophila where loss-of-function mutations can be analyzed for their effect on organ growth. both pten (nelen et al., 1997) and tsc1-2 (mutated in tsc; the european chromosome 16 tuberous sclerosis consortium, 1993; van slegtenhorst et al., 1997) may play coordinating roles in organ size control (goberdhan et al., 1999; tapon et al., 2001). however, pten (but not thus far tsc1-2) mutations are known to promote tumorigenesis, with the gene frequently mutated or lost in advanced neoplasms (li et al., 1997). a connection between pten and tsc1-2 has also been proposed via pten loss of function leading to hyperactivation of the protein kinase pkb/akt, which phosphorylates tuberin (inoki et al., 2002; manning et al., 2002). tuberin phosphorylation has been suggested to negatively regulate the tsc1-2 protein complex, allowing activation of s6k and cell growth (potter et al., 2002).",pmc2172316,1,10,19,1,29
601,integrin,protein,,,uniprot,p05556,plasma membrane,go:0005886,erk,protein,,mapk1,uniprot,p27361,"cytoplasm, nucleus","go:0005737, go:0005634",positive,i,activation,,nih 3t3,fibroblast,,mouse,['2758'],nan,nan,"integrin-mediated adhesion to the extracellular matrix permits efficient growth factor-mediated activation of extracellular signal–regulated kinases (erks). points of regulation have been localized to the level of receptor phosphorylation or to activation of the downstream components, raf and mek (mitogen-activated protein kinase/erk kinase). however, it is also well established that erk translocation from the cytoplasm to the nucleus is required for g1 phase cell cycle progression. here we show that phosphorylation of the nuclear erk substrate, elk-1 at serine 383, is anchorage dependent in response to growth factor treatment of nih 3t3 fibroblasts. furthermore, when we activated erk in nonadherent cells by expression of active components of the erk cascade, subsequent phosphorylation of elk-1 at serine 383 and elk-1–mediated transactivation were still impaired compared with adherent cells. elk-1 phosphorylation was dependent on an intact actin cytoskeleton, as discerned by treatment with cytochalasin d (ccd). finally, expression of active mek failed to predominantly localize erk to the nucleus in suspended cells or adherent cells treated with ccd. these data show that integrin-mediated organization of the actin cytoskeleton regulates localization of activated erk, and in turn the ability of erk to efficiently phosphorylate nuclear substrates.",pmc2169466,1,10,19,1,29
604,ir,protein,receptor,insr,uniprot,p06213,plasma membrane,go:0005886,erk,protein,kinase,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,i,enhance,,,,,,['2672'],nan,nan,"the egfr and ir networks share many downstream components. under some conditions, egf can evoke metabolic responses, e.g., glut4 translocation (ishii et al, 1994; gogg and smith, 2002), whereas insulin can be mitogenic, especially in cancer cells (ish-shalom et al, 1997; papa et al, 1997). there is evidence that insulin can enhance egf-stimulated extracellular signal-regulated kinase (erk) activation, dna synthesis, and cell proliferation responses (crouch et al, 2000; ediger and toews, 2000; chong et al, 2004), whereas growth factors, cytokines, and other hormones can negatively regulate insulin signaling (gual et al, 2003). yet, despite experimental evidence of crosstalk between insulin and growth factor pathways, it is unknown how combined egf and insulin inputs are processed into integrative cellular response. this is at least in part due to the combinatorial complexity of molecular interactions and a variety of feedback and feed-forward loops, whose concerted operation is difficult to comprehend intuitively.",pmc2683723,1,10,19,1,29
669,mkk1,protein,,map2k1,uniprot,p32004,cytoplasm,go:0005737,igf-1,protein,,igf1,uniprot,p05019,extracellular region,go:0005576,positive,d,stimulation,,rh30,unknown,unknown,unknown,['3296'],nan,nan,"(a) rh30 cells, infected with ad-mkk1-r4f, ad-mkk1-k97m, and ad-gfp (control), respectively, were serum-starved for 24 h, pretreated with or without rapamycin (rapa, 100 ng/ml) for 2 h, and then stimulated with or without igf-1 (10 ng/ml) for 15 min, followed by western blotting with indicated antibodies. (b) motility of rh30 cells infected with ad-mkk1-r4f, ad-mkk1-k97m or ad-gfp was determined by the wound healing assay. results are means ± se of 3–4 independent experiments. a",pmc2868031,1,10,19,1,29
1109,tsc2,protein,,tsc2,uniprot,p49815,,,p70s6k,protein,,rps6kb1,uniprot,p23443,,,positive,i,phosphorylation,,,nsclc,,human,['2274'],nan,nan,"tsc1-tsc2 complexes have recently been implicated in cell survival responses. the molecular mechanisms by which tsc2 affects mtor-related signals remain unclear. we found that knockdown of tsc2 resulted in inhibition of the effect of rosiglitazone on the mtor downstream target p70s6k suggesting a role for tsc2 in mediating this effect. in cell proliferation assays, we showed that the tsc2 sirna partially restored nsclc cell growth in the presence of rosiglitazone, although knockdown of tsc2 alone had no effect on nsclc cell proliferation. this suggests that tsc2 does not contribute to nsclc cell proliferation at baseline, but its phosphorylation partially mediates the growth inhibitory effect of rosiglitazone.",pmc1892639,1,10,19,1,29
840,p70s6k,protein,,,uniprot,p23443,,,s6,protein,,,uniprot,p62753,,,negative,d,inhibition,,,nsclc,lung,human,['3033'],nan,nan,"in conclusion, our study demonstrated that the p70s6k inhibitor pf-4708671 could affect cell cycle distribution, inhibiting cell proliferation, apoptosis and invasion in nsclc cells. inhibiting the p70s6k-s6 axis resulted in potent anti-tumor activity. therefore, combination therapy with p70s6k inhibitor and chemotherapy represents a promising new strategy for nsclc treatment.",pmc4714881,1,10,18,1,28
839,p70s6k,protein,,,uniprot,p23443,cytoplasm,go:0005737,s6,protein,,,uniprot,p62753,cytoplasm,go:0005737,negative,d,phosphorylation,,,,,human,['3024'],nan,nan,"our results revealed that the specific p70s6k inhibitor pf-4708671 significantly reduced the phosphorylation of p70s6k and its downstream s6 at 0.1μm (p<0.05); p-s6 expression levels decreased with increasing drug concentrations (p<0.05). on the contrary, protein levels of downstream bad, caspase3 and erk were increased after treatment with pf-4708671 with the concentration of 1μm. however, total p70s6k and s6 protein levels had no significant differences between negative control and treatment groups (fig 1, s1 file).",pmc4714881,1,10,18,1,28
991,s6k1,protein,,s6k1,uniprot,p23443,,,rps6,protein,ribosomal,rps6,uniprot,p62753,cytosol,go:0005829,positive,d,phosphorylation,c-terminal serine sites,,,,,['1438'],nan,nan,"the ribosomal protein s6 (rps6) was the first identified substrate of s6k. it is phosphorylated on five c-terminal serine sites by s6ks in the following sequential order: s236 > s235 > s240 > s244 > s247 [65]. the study of rps6p/− knock-in mice (in which alanine residues replaced the rps6 phosphorylation sites) established that rps6 phosphorylation is crucial for cell size and proliferation since cells isolated from rps6p−/− displayed defective cell growth [66, 67]. s6k1 is very essential for regulating cell and body size as s6k1 null mice are much smaller at birth because of a decrease in the size of all organs [66] and a majority of ds6k null drosophila show embryonic lethality [68]. the study of rps6p−/− mice has also confirmed that the translation of mrnas having a 5′ terminus oligopyrimidine tract (5′top mrnas), a process that was earlier considered to be regulated by rps6 phosphorylation, is not dependent on this event [69].",pmc4258317,1,10,18,1,28
